AR
DRNA

Advisory Research’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Advisory Research’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-18,135
Closed -$333K – 358
2020
Q1 		$333K Sell
18,135
-3,516
-16% -$68.3K 0.02% 234
2019
Q4 		$477K Buy
+21,651
New +$436K 0.02% 244

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Advisory Research's DRNA Position: Q2 2020 in Review

Advisory Research sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q2 2020, closing a stake of 18,135 shares — an estimated $333K sold.

Advisory Research first reported a position in DRNA in Q4 2019 and held it in 2 quarters. The position peaked at $477K in Q4 2019. 170 funds tracked by Wall St. Rank hold DRNA as of Q2 2020.

  • Advisory Research reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • Advisory Research sold 18,135 Dicerna Pharmaceuticals, Inc. shares in Q2 2020, an estimated $333K.
  • Advisory Research first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2019 and held it in 2 quarters.
  • Advisory Research's Dicerna Pharmaceuticals, Inc. position peaked at $477K in Q4 2019.
  • 170 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q2 2020.

Based on Advisory Research's 13F filing for Q2 2020, filed 13 Aug 2020.